Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Detalles Bibliográficos
Autores principales: Fitzgerald, Timothy, Zhdanava, Maryia, Pilon, Dominic, Shah, Aditi, Lefebvre, Patrick, Feldman, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2023
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613165/
https://www.ncbi.nlm.nih.gov/pubmed/37752408
http://dx.doi.org/10.1007/s13555-023-01017-8
_version_ 1785128770093449216
author Fitzgerald, Timothy
Zhdanava, Maryia
Pilon, Dominic
Shah, Aditi
Lefebvre, Patrick
Feldman, Steven R.
author_facet Fitzgerald, Timothy
Zhdanava, Maryia
Pilon, Dominic
Shah, Aditi
Lefebvre, Patrick
Feldman, Steven R.
author_sort Fitzgerald, Timothy
collection PubMed
description
format Online
Article
Text
id pubmed-10613165
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-106131652023-10-30 Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA Fitzgerald, Timothy Zhdanava, Maryia Pilon, Dominic Shah, Aditi Lefebvre, Patrick Feldman, Steven R. Dermatol Ther (Heidelb) Letter Springer Healthcare 2023-09-26 /pmc/articles/PMC10613165/ /pubmed/37752408 http://dx.doi.org/10.1007/s13555-023-01017-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Letter
Fitzgerald, Timothy
Zhdanava, Maryia
Pilon, Dominic
Shah, Aditi
Lefebvre, Patrick
Feldman, Steven R.
Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_full Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_fullStr Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_full_unstemmed Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_short Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
title_sort response to the letter to the editor: long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the usa
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10613165/
https://www.ncbi.nlm.nih.gov/pubmed/37752408
http://dx.doi.org/10.1007/s13555-023-01017-8
work_keys_str_mv AT fitzgeraldtimothy responsetothelettertotheeditorlongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT zhdanavamaryia responsetothelettertotheeditorlongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT pilondominic responsetothelettertotheeditorlongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT shahaditi responsetothelettertotheeditorlongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT lefebvrepatrick responsetothelettertotheeditorlongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa
AT feldmanstevenr responsetothelettertotheeditorlongtermpsoriasiscontrolwithguselkumabadalimumabsecukinumaborixekizumabintheusa

Ejemplares similares